Auspex Pharmaceuticals Reports 2014 First Quarter Results
GlobeNewswire - 1 hr 29 mins ago
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced its financial results for the first quarter ended March 31, 2014.
Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary
Huntington's Disease - Pipeline Review, H1 2014: 50 Company and 93 Drug Profiles
M2 - Wed May 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bgc4/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - GAcadia Pharmaceuticals Inc. - Accera, Inc. - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Aniona ApS - Auspex Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Centre de Regulacio Genomica - Chronos Therapeutics Limited - Cortex Pharmaceuticals, Inc. - CrystalGenomics, Inc. - EncephRx, Inc. - Evotec AG - GW Pharmaceuticals plc - Galenea Corp. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - Treventis Corporation - Trophos SA - UniQure BV - Valens Therapeutics, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - VivaCell Biotechnology Espana S.L. - Vybion, Inc. - Wellstat Therapeutics Corporation - enzyme Corporation - iPierian, Inc Drug Profiles: - pridopidine - SD-809 ER - Coenzyme Q10 - cysteamine DR - PF-02545920 - nabiximols - selisistat - PBT-2 - Epigallocatechin Gallate - BN-82451 - SOM-3355 - OMS-824 - SRX-251 - SRX-246 - SUVN-502 - GSK-356278 - uridine triacetate - Lithium citrate - ALN-HTT - CERE-120 - INDUS-815C - AC-0523 - Xpro-1595 - AN-726 - CX-929 - VAR-10300 - AMT-090 - noscapine - NsG-33 - MTP-131 For more information visit http://www.researchandmarkets.com/research/v2...untingtons
Auspex Pharmaceuticals Appoints Industry Veterans Lynn Bleil And Scott Greer To Its Board Of Directors
PR Newswire - Wed May 07, 7:00AM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the expansion of its Board of Directors with the appointment of two new members:
Auspex (ASPX) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:51AM CDT
Auspex (ASPX) is now in Oversold Territory
Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome
2 Stocks Spiking on Unusual Volume
at The Street - Mon Apr 07, 8:31AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
3 Notable Upcoming IPOs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:57AM CDT
The first three months of 2014 have been very productive for Initial Public Offerings. Here are a few more to consider.
Auspex Pharmaceuticals Added To The Russell 2000® Index
PR Newswire - Mon Mar 31, 3:57PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the Company was added to the Russell 2000® Index (as well as the larger Russell 3000® Index) at the close of market on March 31, 2014 as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes.
Auspex Pharmaceuticals Reports 2013 Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Mar 27, 3:19PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
Auspex Announces The Issuance Of Patents On Deuterium-Containing Form Of Pirfenidone (SD-560)
PR Newswire - Tue Mar 25, 3:01PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the issuance of the following composition of matter and method of treatment patents covering its deuterium-containing form of pirfenidone (SD-560) drug candidate being developed for the potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions:
Auspex To Present at BioCentury's Future Leaders in the Biotech Industry Conference
PR Newswire - Mon Mar 24, 7:00AM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the company will present at BioCentury's Future Leaders in the Biotech Industry conference. The presentation will be delivered by Pratik Shah, Ph.D., President and CEO of Auspex Pharmaceuticals, at 10:30 a.m. EDT on Friday March 28th at the Millennium Broadway Hotel & Conference Center in New York.
Auspex Announces Completion Of Initial Public Offering And Exercise In Full Of Underwriters' Over-Allotment Option
PR Newswire - Mon Feb 10, 3:00PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the completion of its initial public offering of 8,050,000 shares of its common stock at an initial public offering price of $12.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. Auspex's common stock is listed on the NASDAQ Global Market under the trading symbol "ASPX." Auspex expects to use the net proceeds from the offering primarily for the clinical development and commercialization of SD-809, as well as for general corporate purposes.
Auspex prices IPO at USD12.00 per share
M2 - Wed Feb 05, 8:07AM CST
Auspex Pharmaceuticals Inc (Nasdaq:ASPX), a biopharmaceutical company focused on developing and commercialising novel medicines for the treatment of orphan diseases, announced today that it has priced an initial public offering of 7,000,000 shares of its common stock at a public offering price of USD12.00 per share.
Auspex Announces Pricing Of Initial Public Offering
PR Newswire - Tue Feb 04, 11:07PM CST
Auspex Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a public offering price of $12.00 per share. Auspex has granted the underwriters a 30-day option to purchase up to an aggregate of 1,050,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Global Market, beginning on February 5, 2014, under the symbol "ASPX." The offering is expected to close on February 10, 2014, subject to customary closing conditions.